Pasithea Therapeutics shares were up 67% to $3.46 in premarket trading after the company said that an external safety review committee recommended that its Phase 1 clinical trial of PAS-004 in ...

(RTTNews) - Pasithea Therapeutics Corp (KTTA), a clinical-stage biotechnology company, on Tuesday, announced the opening of three new clinical trial sites in Eastern Europe, say Romania and ...

Pasithea Therapeutics Corp. has announced the opening of three clinical trial sites in Romania and Bulgaria for its Phase 1 trial of PAS-004, a macrocyclic MEK inhibitor aimed at treating ...

Pasithea Therapeutics Corp., a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other ...

Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine ...

Pasithea Therapeutics (KTTA) announced it has opened three clinical trial sites in Eastern Europe. These sites in Romania and Bulgaria are actively recruiting patients along with the four open ...

MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea” or the "Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...